Benralizumab is used to treat severe eosinophilic asthma in people aged 6 and older. It helps reduce asthma attacks by lowering the number of eosinophils (a type of white blood cell) in the body, which contribute to airway inflammation.

Benralizumab is given as a subcutaneous (under the skin) injection, typically by a doctor or a nurse. After the initial three doses, which are given once every 4 weeks, the injections are spaced out to once every 8 weeks.

Some patients may notice improvements in their asthma symptoms within the first few weeks, but it can take a few months for the full benefits of Benralizumab to be seen. Adherence to the dosing schedule is important to achieve the best results.

Yes. Benralizumab is often used alongside other asthma medications, such as inhalers or corticosteroids. It is important not to stop any medications without your doctor's approval, even if you feel better.

You should avoid live vaccines while being treated with Benralizumab, as the medicine may weaken your immune response. Non-live vaccines are generally safe, but consult your doctor before receiving any vaccinations.

The safety of Benralizumab during pregnancy and breastfeeding is not fully understood. If you are pregnant, planning to become pregnant, or breastfeeding, talk to your doctor about the risks and benefits of using the medicine.

No, Benralizumab does not cure asthma, but it helps manage and control symptoms in people with severe eosinophilic asthma. It reduces the frequency of asthma attacks and improves overall lung function when used regularly as prescribed.

There are no specific dietary restrictions with Benralizumab, but avoid stopping your asthma medications suddenly or skipping doses. Additionally, live vaccines should be avoided. Always consult your doctor before making any changes to your treatment plan.